Results 221 to 230 of about 208,148 (266)

Transgenic Mouse Models of BCR/ABL-Positive Chronic Myelogenous Leukemia: A Review

Current Genomics, 2005
K. Inokuchi
openaire   +3 more sources

Human medicines European public assessment report (EPAR): Tasigna, nilotinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 19/11/2007, Revision: 33, Status: Authorised

Case Medical Research, 2019
openaire   +2 more sources

Flow cytometric assay of phosphotyrosine levels in Bcr-Abl-positive chronic myelogenous leukemias: a potential prognostic marker

Annals of Hematology, 2008
Assay of phosphotyrosine levels using flow cytometry has been used to identify patients with chronic myelogenous leukemia positive for the Bcr-Abl fusion gene. We hypothesized that clinical monitoring could identify treatment response through reductions in intragranulocyte phosphotyrosine.
Yong-gong Yang, Yu-Jie Wu, Junhao Chen, Xue-Mei Sun, Dong Li, Wei Xu, Wei Xie, Lei-lei Chen, Jianyong Li, Pengjun Jiang   +9 more
openaire   +3 more sources

Absence of the hybrid bcr‐abl mRNA in Ph¹‐positive B lymphoblastoid cell lines established from a patient with chronic myelogenous leukemia [PDF]

International Journal of Cancer, 1987
AbstractThe expression of c‐abl, c‐sis, c‐myc and N‐ras oncogenes was examined in 2 lymphoblastoid cell lines, one with Ph1 (PB‐1049) and the other without Ph1 (LN‐1049), both established from a patient with chronic myelogenous leukemia (CML), and in a Ph1‐positive cell line (PB‐1049‐T) derived from a tumor formed after transplantation of PB‐1049 cells
Tsuneyuki Oikawa, Toshiyuki Yamada, Noboru Kuzumaki, Motomichi Sasaki, Nobuo Takagi   +4 more
openaire   +2 more sources

Human medicines European public assessment report (EPAR): Imatinib medac, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Dermatofibrosarcoma,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome, Date of authorisation: 25/09/2013, Revision: 5, Status: Withdrawn

Case Medical Research, 2019
openaire   +2 more sources

Relationship of the type of bcr-abl hybrid mRNA to clinical course and transforming activity in philadelphia-positive chronic myelogenous leukemia

Leukemia Research, 1992
We studied the type of bcr-abl mRNA for 34 patients with chronic myelogenous leukemia and analyzed for correlations among the mRNA type, the clinical outcome and the transforming activity using the tumorigenicity assay. There was no difference in the distribution of the mRNA-types (b2-a2 and b3-a2) between clinical phases.
Takeo Nomura, Kazuo Dan, Hiroki Matsuoka, Koichi Miyake, Koiti Inokuchi, Makoto Futaki   +5 more
openaire   +3 more sources

Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL-Positive Chronic Myelogenous Leukemia Treated with Ruxolitinib and Dasatinib.

Blood, 2012
Abstract Abstract 2832 Co-occurrence of a JAK2 V617F-positive myeloproliferative neoplasm (MPN) with BCR-ABL-positive chronic myelogenous leukemia (CML) in a single patient is rare. Previous reports have suggested that the two disorders may arise independently or within the same clone, but definitive clonal analysis has ...
Deborah M. Moore, Daniel A.C. Fisher, Jonathan L. Klein, Stephen T. Oh, Li He, Eric M. Knoche, Gregory Rippberger   +6 more
openaire   +2 more sources

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

Blood, 2000
Targeting the tyrosine kinase activity of Bcr-Abl with STI571 is an attractive therapeutic strategy in chronic myelogenous leukemia (CML). A few CML cell lines and primary progenitors are, however, resistant to this compound.
F. Mahon, M. Deininger, B. Schultheis, J. Chabrol, J. Reiffers, J. Goldman, J. Melo   +6 more
semanticscholar   +1 more source

Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up

Cancer Genetics and Cytogenetics, 2006
The case of an 11-year-old child with adult-type chronic myeloid leukemia, Philadelphia (BCR-ABL) positive, reverse transcription-polymerase chain reaction negative for the major, minor, and micro breakpoints is presented. In the course of 3 years, the child failed to respond to treatment with hydroxyurea, refused all therapy for 6 months, was ...
Asher Moser, Ginat Narkis, Esther Manor, Joseph Kapelushnik   +3 more
openaire   +3 more sources

Philadelphia-positive chronic myelogenous leukemia with typical bcr/abl molecular features and atypical, prolonged survival.

Leukemia, 1989
Despite the major breakthrough in the knowledge of the molecular events underlying the t(9;22) translocation, still no consistent data have been found on the evolution of Ph1 positive CML from the chronic to the accelerated or blastic phase of the disease.
Selleri L., Emilia G., Temperani P., Grassilli E., Zucchini P., Tagliafico E., Bonati A., Venezia L., Ferrari S., Torelli U., Torelli G.   +10 more
openaire   +2 more sources